A compound for use in the treatment of cancer, an immune disease, Parkinson's disease, Cardiac Hypertrophy or Type-2 diabetes, said compound having a structure according to Formula I wherein X is selected from the group consisting of N; R 1 is selected from the group consisting of hydrogen, (C 1 -C 6)alkyl, (C 1)haloalkyl, (C 3 -C 8)cycloalkyl, (C 6 -C 10)aryl, (C 6 -C 10)aryl(C 1 -C 6)alkyl,; R 2 and R 3 are independently selected from the group consisting of hydrogen, (C 1 -C 2)alkyl,; n is an integer between 0 and 2; Z is selected from the group consisting of C=O,; A is selected from the group consisting of-N(R 4)(R 5) and R 4 is hydrogen or (C 1 -C 6)alkyl; R 5 is selected from the group consisting of (C 6 -C 10)aryl(C 1 -C 6)alkyl, (C 3 -C 10)heteroaryl(C 1 -C 6)alkyl, (C 3 -C 10)heteroaryl(C 1 -C 6)heteroalkyl and (C 6 -C 10)aryl(C 1 -C 6) heteroalkyl, which are optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, (C 1 -C 4)alkyl, (C 1 -C 4)haloalkyl and -OR 6; R 6 is (C 1 -C 4)alkyl or (C 1 -C 4)haloalkyl; Y 1 is selected from the group consisting of N-B, CH-B and O; B is selected from the group consisting of (C 6 -C 10)aryl, (C 3 -C 10)heteroaryl, (C 6 -C 10)aryl(C 1 -C 6)alkyl, (C 3 -C 10)heteroaryl(C 1 -C 6)alkyl, (C 1 -C 6)alkyl and N(R 7)(R 8), which are optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, (C 1 -C 4)alkyl, (C 1 -C 4)haloalkyl and -OR 6; R 7 is hydrogen or (C 1 -C 6)alkyl; R 8 is selected from the group consisting of (C 6 -C 10)aryl, (C 3 -C 10)heteroaryl, (C 6 -C 10)aryl(C 1 -C 6)alkyl, C 3 -C 10)heteroaryl(C 1 -C 6)alkyl and (C 1 -C 6)alkyl; p is an integer between 1 and 2; q is an integer between 1 and 3; or a pharmaceutically acceptable salt, solvate or hydrate thereof. X is selected from the group consisting of N; R 1 is selected from the group consisting of hydrogen, (C 1 -C 6)alkyl, (C 1)haloalkyl, (C 3 -C 8)cycloalkyl, (C 6 -C 10)aryl, (C 6 -C 10)aryl(C 1 -C 6)alkyl,; R 2 and R 3 are independently selected from the group consisting of hydrogen, (C 1 -C 2)alkyl,; n is an integer between 0 and 2; Z is selected from the group consisting of C=O,; A is selected from the group consisting of-N(R 4)(R 5) and R 4 is hydrogen or (C 1 -C 6)alkyl; R 5 is selected from the group consisting of (C 6 -C 10)aryl(C 1 -C 6)alkyl, (C 3 -C 10)heteroaryl(C 1 -C 6)alkyl, (C 3 -C 10)heteroaryl(C 1 -C 6)heteroalkyl and (C 6 -C 10)aryl(C 1 -C 6) heteroalkyl, which are optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, (C 1 -C 4)alkyl, (C 1 -C 4)haloalkyl and -OR 6; R 6 is (C 1 -C 4)alkyl or (C 1 -C 4)haloalkyl; Y 1 is selected from the group consisting of N-B, CH-B and O; B is selected from the group consisting of (C 6 -C 10)aryl, (C 3 -C 10)heteroaryl, (C 6 -C 10)aryl(C 1 -C 6)alkyl, (C 3 -C 10)heteroaryl(C 1 -C 6)alkyl, (C 1 -C 6)alkyl and N(R 7)(R 8), which are optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, (C 1 -C 4)alkyl, (C 1 -C 4)haloalkyl and -OR 6; R 7 is hydrogen or (C 1 -C 6)alkyl; R 8 is selected from the group consisting of (C 6 -C 10)aryl, (C 3 -C 10)heteroaryl, (C 6 -C 10)aryl(C 1 -C 6)alkyl, C 3 -C 10)heteroaryl(C 1 -C 6)alkyl and (C 1 -C 6)alkyl; p is an integer between 1 and 2; q is an integer between 1 and 3; or a pharmaceutically acceptable salt, solvate or hydrate thereof.